Literature DB >> 18308165

Survival and cardiac remodeling benefits in patients undergoing late percutaneous coronary intervention of the infarct-related artery: evidence from a meta-analysis of randomized controlled trials.

Antonio Abbate1, Giuseppe G L Biondi-Zoccai, Darryn L Appleton, Paul Erne, Andreas W Schoenenberger, Michael J Lipinski, Pierfrancesco Agostoni, Imad Sheiban, George W Vetrovec.   

Abstract

OBJECTIVES: Our purpose was to perform a systematic review and meta-analysis of randomized trials comparing percutaneous coronary intervention (PCI) of the infarct-related artery (IRA) with medical therapy in patients randomized >12 h after acute myocardial infarction (AMI).
BACKGROUND: There is ongoing uncertainty about the risk-benefit ratio of late PCI in stable patients with AMI.
METHODS: PubMed, CENTRAL, and other databases were searched (July 2007). Studies were included if they compared PCI with medical management and randomized patients >12 h and up to 60 days after AMI, and were excluded if patients were hemodynamically unstable. Odds ratios (ORs) were pooled for dichotomous outcomes, with all-cause mortality as the primary end point. Left cardiac remodeling parameters were also pooled with generic inverse-variance weighting.
RESULTS: We retrieved 10 studies that enrolled 3,560 patients, with median time from AMI to randomization of 12 days (range 1 to 26 days), and follow-up of 2.8 years (42 days to 10 years). Randomization allocated 1,779 subjects to PCI and 1,781 to medical treatment. There were 112 (6.3%) and 149 (8.4%) deaths in the 2 groups, respectively, yielding significantly improved survival in the PCI group (OR 0.49 [95% confidence interval (CI) 0.26 to 0.94], p = 0.030). These benefits were associated with similarly favorable effects on cardiac remodeling, such as improved left ventricular ejection fraction in the PCI group (+4.4% change [95% CI 1.1 to 7.6], p = 0.009).
CONCLUSIONS: Percutaneous coronary intervention of the IRA performed late (12 h to 60 days) after AMI is associated with significant improvements in cardiac function and survival.

Entities:  

Mesh:

Year:  2008        PMID: 18308165     DOI: 10.1016/j.jacc.2007.11.062

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  24 in total

Review 1.  Putting the benefits of percutaneous coronary revascularization into perspective: from trials to guidelines.

Authors:  Kamal Sharma; Mark J Eisenberg
Journal:  Curr Cardiol Rep       Date:  2008-09       Impact factor: 2.931

2.  Survival benefit of the late percutaneous coronary intervention in the patients after acute myocardial infarction who are or who are not treated with thrombolysis.

Authors:  Bozidarka Knezević; Nebojsa Bulatović; Natasa Belada; Vesna Ivanović; Sinisa Dragnić; Miroslav Rabrenović; Goran Nikolić; Ljilja Musić; Aneta Bosković
Journal:  Bosn J Basic Med Sci       Date:  2009-02       Impact factor: 3.363

3.  Myocardial salvage after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction presenting early versus late after symptom onset.

Authors:  Thomas Stiermaier; Ingo Eitel; Suzanne de Waha; Janine Pöss; Georg Fuernau; Holger Thiele; Steffen Desch
Journal:  Int J Cardiovasc Imaging       Date:  2017-04-24       Impact factor: 2.357

4.  Meta-analysis of safety for low event-rate binomial trials.

Authors:  Jonathan J Shuster; Jennifer D Guo; Jay S Skyler
Journal:  Res Synth Methods       Date:  2012-03       Impact factor: 5.273

5.  The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone.

Authors:  James E Udelson; Camille A Pearte; Carey D Kimmelstiel; Mariusz Kruk; Joseph A Kufera; Sandra A Forman; Anna Teresinska; Bartosz Bychowiec; Jose Antonio Marin-Neto; Thomas Höchtl; Eric A Cohen; Paulo Caramori; Benita Busz-Papiez; Christopher Adlbrecht; Zygmunt P Sadowski; Witold Ruzyllo; Debra J Kinan; Gervasio A Lamas; Judith S Hochman
Journal:  Am Heart J       Date:  2011-03       Impact factor: 4.749

6.  Methylenetetrahydrofolate reductase (MTHFR) C677T genetic polymorphism and late infarct-related coronary artery patency after thrombolysis.

Authors:  Giuseppe Patti; Carolina Fossati; Annunziata Nusca; Simona Mega; Vincenzo Pasceri; Andrea D'Ambrosio; Barbara Giannetti; Ombretta Annibali; Giuseppe Avvisati; Germano Di Sciascio
Journal:  J Thromb Thrombolysis       Date:  2008-06-25       Impact factor: 2.300

7.  Invasive reperfusion after 12 hours of the symptom onset remains beneficial in patients with ST-segment elevation myocardial infarction: Evidence from a meta-analysis of published data.

Authors:  Hai-Tao Yang; Wen-Juan Xiu; Ying-Ying Zheng; Fen Liu; Ying Gao; Xiang Ma; Yi-Ning Yang; Xiao-Mei Li; Yi-Tong Ma; Xiang Xie
Journal:  Cardiol J       Date:  2018-04-03       Impact factor: 2.737

8.  Changes in the safety paradigm with percutaneous coronary interventions in the modern era: Lessons learned from the ASCERT registry.

Authors:  Alfredo E Rodríguez; Carlos Fernández-Pereira; Alfredo M Rodríguez-Granillo
Journal:  World J Cardiol       Date:  2012-08-26

Review 9.  Chemical genetics and its potential in cardiac stem cell therapy.

Authors:  Joaquim M Vieira; Paul R Riley
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

10.  In-hospital outcomes of delayed stenting in hemodynamically stable patients with ST-segment elevation myocardial infarction: the CCC (Care for Cardiovascular Disease in China) project.

Authors:  Jia-Wei Wu; Hao Hu; Dan Li; Li-Kun Ma
Journal:  Cardiovasc Diagn Ther       Date:  2019-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.